Cardiora Pty Ltd

Level 9, 31 Queen St, Melbourne VIC 3000

ABN: 33 606 313 642

+613 9657 0700

News and Updates

2019:

  • Cardiora to publish phase 2a HFpEF trial results at ACC19 Scientific Sessions

2018:

  • Cardiora’s RHF in LVAD indication granted Orphan designation by the FDA, commences phase 1b IND trial in University of Chicago

  • Cardiora completes phase 2a HFpEF trial

2017:

  • Cardiora completes phase 2a HFrEF trial

2016:

  • Cardiora presents proof of concept data for use of milrinone to treat HFpEF at ACC16 Scientific Sessions

  • Cardiora commences phase 2a trial in HFpEF patients

2015: